ESMO 2023: Perioperative Durvalumab + Neoadjuvant Chemotherapy Tied to Improved Survival in Resectable NSCLC
The combination treatment improved duration of event-free survival
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.